Latest news on Alzheimer's clinical trials, drug testing, and new therapies.
38 articles found
A large study has found that women who used hormone therapy later in life had a lower risk of developing dementia. The findings were published August 12, 2026, in Neurology, the medical journal of the...
Use of hormone therapy later in life was associated with lower risk of developing dementia, according to a study published August 12, 2026, in Neurology®, the medical journal of the American Academy o...
People with both atrial fibrillation and Alzheimer's disease who are treated with modern NOAC blood-thinning medicines may experience a slower rate of cognitive decline. This is shown by a study from ...
Many people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow the disease, according to a study published August 5, 2026, in Neurology®, ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions as...
A combination of CBD and THC rapidly and significantly reduces agitation in hospice-eligible people with dementia, suggest topline results from the Phase 2 LiBBY (Life's End Benefits of cannaBidiol an...
In a first-of-its-kind clinical trial, U.S. researchers have found that people with agitation and dementia in late life who took a special medical formulation of two active ingredients found in mariju...
The Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN), a global collaboration of academic researchers, pharmaceutical companies, and philanthropic organizat...
Accumulation of DNA damage in the brain's neurons may contribute to the development of Alzheimer's disease. New research in FEBS Open Bio demonstrates the therapeutic potential of a drug that targets ...
As depression accelerates suffering in Alzheimer’s and Parkinson’s disease, researchers argue that the next generation of treatments must target the damaged brain circuits and molecular pathways that ...
Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatm...
A substance that worsens dementia has become a "switch" that initiates treatment. KAIST researchers have developed a new therapeutic approach that uses hydrogen peroxide (H₂O₂), a reactive oxygen spec...
Monash University researchers have found in laboratory experiments that a drug which delivers copper to the brain significantly reduces toxic Alzheimer's proteins and improves long-term spatial memory...
Researchers from ETH Zurich have developed an active ingredient that slows down the progression of typical Alzheimer’s symptoms in mice. This new substance protects nerve cells and could in future all...
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (LeqembiTM, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunoth...
New Alzheimer’s drugs are raising hopes, but modest benefits, ARIA safety risks, high costs, and regulatory disagreements show how uncertain the path to meaningful treatment remains. From hope to unc...
A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the drugs work, according to a new study led by researchers at the Brown Universit...
Lithium chloride may affect many cellular level changes in Alzheimer's disease, a new study from the University of Eastern Finland (UEF) shows. Alzheimer's disease (AD) is the most common form of dem...
The U.S. Food and Drug Administration (FDA) has approved a new first-in-class treatment, Auvelity (dextromethorphan-bupropion), for the treatment of agitation associated with Alzheimer’s disease. Auv...
Despite successfully removing amyloid plaques from the brain, widely anticipated antibody therapies fail to deliver meaningful cognitive improvements, raising critical questions about the future direc...
AlzeCure Pharma AB, a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the last patient’s last vi...
Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has f...
A new study finds that combining the current medications for Alzheimer's disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more eff...
The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatmen...